Clinical Trial Update: Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing tiragolumab plus atezolizumab versus atezolizumab alone in ctDNA-positive Stage II melanoma after resection has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Stage II Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2024-02-15